Cipla share price: In a press release issued after market hours on February 20, Cipla announced that it has received approval for Nilotinib capsules in 50 mg, 150 mg, and 200 mg strengths. The oral ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...

Mumbai: Pharma major, Cipla, has received final approval from the United States Food and Drug Administration (USFDA) for the New Drug Application (‘NDA’) submitted for ‘Nilotinib Capsules 50, 150 and ...

Cipla announced that it has received final approval from the United States Food and Drug Administration (USFDA) for the new drug application (NDA) submitted for 'Nilotinib Capsules 50, 150 and 200 mg' ...

Cipla's product portfolio spans complex generics as well as drugs in the respiratory anti-retroviral urology cardiolo... In compliance with regulation 30 of SEBI (Listing Obligations and Disclosure ...

Cipla has got final approval from the USFDA for New Drug Application (NDA) for its Nilotinib Capsules 50 mg, 150 mg and 200 mg respectively. Nilotinib is an FDA approved drug used for the ...

So, within the generic companies, from the US point of view, Cipla delivered a very good set of results supported by the niche launches. And if you see, the commentary has also been very positive.

drug shortage list nearly four months after the agency found the drugs to be available. The FDA’s drug shortage list now states that as of Feb. 21, 2025, the shortages of Ozempic and Wegovy ...